Johnson & Johnson

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J’s Spravato for depression ‘should be much cheaper’

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body.

News

AZ prepares for showdown with AbbVie/J&J as Calquence shines...

AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.

News

J&J unveils early-stage prostate cancer data from Erleada at...

Johnson & Johnson is hoping to expand the use of its prostate cancer drug Erleada (apalutamide) in patients with metastatic castration-sensitive prostate cancer (mCSPC) – and new data p

News

Owlstone's ReCIVA is being developed to diagnose lung cancer, but also has applications in precision medicine trials

Owlstone signs deal with J&J's Actelion for PH breath test

UK-based Owlstone Medical has signed a deal with Johnson & Johnson’s Actelion unit, to discover and validate a breath-based test for early diagnosis of pulmonary hypertension.<

News

Gilead faces lawsuit over HIV drug pricing

Gilead and other pharma companies stand accused of engaging in a scheme to block cheaper competitors to life-saving HIV drugs from entering the market.

News